Latest Market Speculation News

Staude Capital Global Value Fund Limited (GVF) has responded to ASX concerns over a media article revealing details of its capital raising before official announcement, denying any direct media disclosures and reaffirming its compliance policies.

Brightstar Resources and Aurumin Limited have entered live merger discussions to consolidate their Central Sandstone tenements, aiming to create a major gold development project with a combined resource of approximately 2.4 million ounces. The proposed deal offers Aurumin shareholders a premium and could accelerate development and infrastructure plans in Western Australia’s Goldfields.

Brightstar Resources and Aurumin Limited have entered live merger discussions to consolidate their Central Sandstone tenements, aiming to create a major gold development project with a combined resource of approximately 2.4 million ounces. The proposed scrip deal offers Aurumin shareholders a premium, though completion remains uncertain pending due diligence.

New World Resources has received a conditional, non-binding takeover proposal from Kinterra Capital to acquire all remaining shares at A$0.057 each. The board is currently reviewing the offer amid ongoing market speculation.

Centuria Capital Group announces a 5.20 cents per stapled security final distribution for June 2025, suspending its Distribution Reinvestment Plan for this payout.

Simble Solutions Limited has voluntarily suspended its ASX trading pending a capital raising announcement, signaling a significant funding move for the software company.

Western Gold Resources has voluntarily suspended its shares from trading as it prepares to disclose details of a significant agreement and respond to an ASX price query.

Codeifai Limited has addressed ASX concerns over unusual trading activity, confirming awareness of undisclosed information and releasing a status update on proposed transactions.

REA Group has confirmed it is under investigation by the ACCC concerning its subscription offerings, signaling potential regulatory scrutiny for the property tech giant.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.